PROPULSID
LOE ApproachingNDAORALSUSPENSION
Approved
Sep 1995
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 19h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
PROPULSID (generic name unknown) is an oral suspension approved by the FDA in 1995 as a small-molecule NDA. The specific mechanism of action and clinical indications are not documented in available data, limiting characterization of its therapeutic role.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30%), indicating a brand team focused on managed decline and generic transition planning.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings and approaching LOE status indicate this product offers limited career momentum or expansion opportunities. Career value lies primarily in managed transition and cost-containment strategy execution.
Brand ManagerProduct Manager
Worked on PROPULSID at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.